Homepage Top Section1

The mid-stage trial met the primary endpoint by recording a statistically significant improvement from baseline in motor symptoms in patients treated with tavapadon in comparison with those in

The partnership will see compounds from the retinal disease pipeline portfolio of Boehringer Ingelheim combined with the intravitreal (IVT) drug delivery technologies of Inflammasome. Inflammasome’s technology will be

The status was provided based on data from the phase II NOBILITY study in adult patients with proliferative lupus nephritis. Gazyva, in combination with standard of care (mycophenolate

Keytruda is Merck’s anti-PD-1 therapy, while Lenvima is the orally available kinase inhibitor discovered by Eisai. Keytruda plus Lenvima has been approved for the treatment of patients with

The Allergenic Products Advisory Committee (APAC) voted seven to two that the efficacy data and eight to one that the safety data, along with other safeguards, are enough

Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval

The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent

The ASPIRE I and II trials evaluated the efficacy and safety of esketamine nasal spray in 465 patients with the moderate-to-severe major depressive disorder who have active suicidal

Ofev has been indicated for slowing the rate of decline in pulmonary function in adult patients with SSc-ILD, which makes it the first FDA-approved treatment for the rare